The AVF Fellows Course in Venous Disease will be held at Englewood Hospital and Medical Center, Englewood, NJ. May 6,7,8.
Course Director, Steve Elias MD FAC S FAC Ph. The course is sponsored by the American Venous Forum. Qualified attendees can be fellows in training for: vascular surgery, interventional radiology, vascular medicine, phlebology, etc. The course is both didactic and hands-on and industry
supported.
InaVein, LLC Announces First Peer-reviewed Publication of TRIVEX® Used In-Office
LEXINGTON , MA —InaVein, LLC today announced publication of a peer-reviewed paper that examines use of the TRIVE X transilluminated powered phlebectomy (TI PP) System for removal of varicose veins in a clinical office rather than a hospital setting. The paper, Transilluminated Powered Phlebectomy in an Office Setting: Procedural Considerations and Clinical Outcomes was authored by Gregory A. Spitz, M.D., FAC S (AmeriVein Systems, Aurora, Illinois) and published in the October 2011 edition of the Journal of Endovascular Therapy. The TRIVE X procedure was successfully completed on all patients using only local tumescent anesthesia. There were no reports of hematomas, deep vein thrombosis, or extended parasthesia at the 3-month follow up. Patients reported a high level of satisfaction (9.6 out of 10) in this setting. A mean procedure time of 13.5 minutes (+/-3.7 min) was reported. Thirtythree of the 36 patients underwent concurrent endovenous ablation procedures. According to Dr. Spitz, “More recent cases have confirmed that when patients are prepared for an in-office procedure and treated by a physician well versed in the TI PP procedure and tumescent anesthesia, the outcomes are mutually satisfying. There should also be an economic benefit, with reduced cost to the healthcare system, as has been realized in other clinical situations.” InaVein CEO Keith Jansen said, “This clinical evidence highlights the benefits of the TRIVE X procedure in an office environment for patients who have varicose veins -- a condition that impacts 25 - 40 million Americans and over 700 million people globally.”
About InaVein
InaVein, LLC is a privately held company engaged in the development, manufacture, marketing and commercialization of unique medical devices for the treatment of vein disease. The company’s flagship product, The TRIVE X System, is the first technology to provide vein specialists with a minimally invasive technique to remove varicose veins safely and efficiently under direct vision. Since 2003, thousands of patients worldwide have been successfully treated using The TRIVE X System in a surgical setting to completely remove their varicose veins. For more information please visit www.inavein.com or call (617) 245-1965
BioMedix™ Appoints Eric Bosler as VP, Finance & Chief Financial Officer (WE HAVE PHOTO)
Saint Paul, MN –BioMedix™, a leader in Health Information Technology (HIT ) software, products and services, announces the appointment of Eric Bosler as Vice President, Finance and Chief Financial Officer (CFO). Mr. Bosler will provide financial leadership for the company and serve as akey member of the executive management team.
“I am excited to join BioMedix™ at this stage of growth, and look forward to working with the executive team to continue to build the company as a leading provider of medical devices and Health Information Technology,” said Mr. Bosler.
Mr. Bosler brings over 18 years of medical device, financial management and operational experience to the BioMedix™ executive team. He has extensive leadership experience in both start-up and large organizations, as well as crossfunctional and non-finance experience leading a program management office. He has held positions at respected companies such as Medtronic, Survivalink and Ernst & Young, while finding time to volunteer in the community. During his 13 years with Medtronic, Mr. Bosler served in a number of leadership positions, most recently as Senior Finance Director for US Commercial Operations within the Cardiovascular Business Unit, supporting over a billion dollars in revenue across multiple direct selling organizations. Mr. Bosler has a proven ability to identify and address key business opportunities, develop innovative solutions and effectively implement change.
“We are pleased to welcome Eric to BioMedix™,” said John Romans, BioMedix™ President and CEO , “With his outstanding history of achievement through business partnership and collaboration, he will be instrumental to supporting the continued evolution of our company.”
Mr. Bosler is a Certified Public Accountant (inactive license) and is co-inventor on two US Patents related to defibrillation waveforms. He holds a BA in Social Science from Colorado State University and a MBA with an Accounting specialization from the Daniels College of Business at the University of Denver.
About BioMedix™
BioMedix™ is a leader in Health Information Technology (HIT ) software, products and services that connect podiatric physicians, primary care physicians, vascular labs, vascular specialists and healthcare systems in a continuum of collaborative care. We provide the only integrated suite of hardware, software and online services designed to costeffectively detect vascular disease. Our award-winning suite of medical devices, advanced practice management and Electronic Health Record (EHR) software and web-based solutions give providers a more complete view of patient care. For more information about BioMedix™ products, call 877-854-0014 or log on to www.BioMedix.com.
SIGVARIS’ Exciting New Fashion Addition For Women Keeps Legs Healthy and Helps Prevent Varicose Veins
Peachtree City, GA —SIGVARI S, the global leader in medical compression hosiery and DVT prevention advocate, is excited to announce that the company is once again keeping its promise of delivering women the most fashionable medical compression hosiery on the market. SIGVARI S’ stylish Soft Opaque Hosiery Line is now available in a 30-40mmHg compression level for those women that need a stronger compression level due to having a recent vein procedure or as a treatment for chronic venous disorders.
“This one-of-a-kind luxury line of medical compression stockings is still being offered in the 15-20mmHg and 20- 30mmHg compression levels,” says Byron MacPhee, Vice President of Sales for the United States. “However, by adding the 30-40mmHg compression level to the line, more women will have an opportunity to experience the lasting microfiber softness of Soft Opaque.”
Soft Opaque not only looks like designer fashion tights, but also works behind the scenes to help keep legs healthy. It features graduated compression, which helps improve circulation and aids in the prevention of varicose and spider veins.
The Soft Opaque Line is available in knee-highs, thighhighs and pantyhose. The pantyhose style may be worn as tights or leggings, to help mask any problem areas that women do not want others to see. The entire fashionable line is available in Midnight Blue, Espresso, Graphite, Black and Nude.
SIGVARIS medical compression hosiery promotes leg health and is universally recommended for both the surgical and non-surgical treatment of venous disorders. In addition to being incredibly soft, the product is also extremely durable.
To learn more about keeping your legs healthy, visit http:// www.sigvarisusa.com. Learn more about Soft Opaque at http://www.SoftOpaque.com.
About SIGVARIS
SIGVARI S® North America is part of an internationally active medical device group headquartered in Winterthur,
Switzerland that focuses on the development, production and distribution of medical compression garments, including hosiery and socks. With distribution in more than 50 countries on six continents, SIGVARI S is recognized as a global industry leader in the area of compression therapy for the management of chronic venous disorders. Our US manufacturing plant is located in Peachtree City, GA . For more information, please visit http://www.sigvarisusa.com. SIGVARIS, LIFE FOR LEGS and the leg icon are trademarks of SIGVARIS AG in Switzerland and are registered in many countries worldwide.
New Data Presented on Phase 3 Trial of ELIQUIS(R) (apixaban) in the Prevention of Venous Thromboembolism in Patients with Acute Medical Illness
In ADO PT, Apixaban did not Meet the Primary Efficacy Outcome of Superiority to Enoxaparin for the Endpoint of VTE and VTE -related Death
PRINCETON , N.J. & NEW YOR K—Numerically Lower Number of Events Observed in the Apixaban Arm Did not Meet Statistical Significance--Key Safety Outcome of Major Bleeding Occurred More in the Apixaban Arm and was Low in Both Groups
Bristol-Myers Squibb Company BMY +0.13% and Pfizer Inc. PFE -0.05% today announced the results of the Phase 3 ADO PT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE ) and VTE - related death at day 30. The apixaban arm had a 13 percent lower rate of events than enoxaparin followed by placebo, which favored apixaban but was not statistically significant and thus no clinically directive conclusion can be drawn. The key safety outcome of major bleeding was low in both groups but occurred in more patients treated with apixaban than with enoxaparin (0.47 percent of patients in the apixaban group and 0.19 percent of patients in the enoxaparin group (P=0.04)). The study results were presented during a latebreaking session at the annual American Heart Association
(AHA) Scientific Sessions in Orlando, FL, and published in the New England Journal of Medicine.
“Solving the problem of VTE post-hospitalization remains a critical unmet need in preventing medically ill patients from developing deep vein thrombosis and pulmonary embolism,” said Dr. Samuel Z. Goldhaber, senior cardiologist at Brigham and Women’s Hospital, and Professor of Medicine, Harvard Medical School, Boston, MA . “ADO PT provides important insights for clinical trialists designing studies of extended duration VTE prophylaxis among medically ill hospitalized patients.”
ELIQUIS (R) (apixaban), a new oral direct Factor Xa inhibitor, is part of a class of agents being studied for their potential to prevent and treat blood clots in multiple indications. ELIQUIS is currently approved in the 27 countries of the European Union (EU) for the prevention of VTE in adult patients who have undergone elective total hip or knee replacement surgery.
About ADOPT
ADO PT was a Phase 3, international, multicenter, randomized, double-blind, controlled study that compared apixaban to enoxaparin in acutely ill medical patients. Patients hospitalized with an expected stay of at least three days were randomly assigned to either oral apixaban (2.5 mg twice daily) for 30 days or to subcutaneous enoxaparin (40 mg once daily). Patients in the enoxaparin arm received treatment for a minimum of 6 days and a maximum of 14 days. Patients randomized to apixaban received daily injections of enoxaparin placebo for a minimum of 6 days and patients randomized to enoxaparin received apixaban placebo tablets for 30 days.
Of the 6,758 patients from 35 countries enrolled in the study, 6,528 patients were randomized for the analysis of the primary efficacy outcome defined as the composite of VTE -related death, fatal or non-fatal pulmonary embolism (PE), symptomatic or asymptomatic deep vein thrombosis (DVT ) as detected by ultrasound and occurring within the 30-day intended treatment period. The statistical plan for the study required testing superiority of apixaban during the intended treatment period before testing for non-inferiority in the injectable treatment period.
When apixaban was compared to enoxaparin, the primary efficacy endpoint occurred in 2.71 percent of patients in the apixaban group and 3.06 percent of patients in the enoxaparin group, demonstrating a non-significant relative risk reduction for apixaban of 13 percent that was not superior to a shorter course of enoxaparin (P=0.44 ).
In ADO PT, the rate of dropouts was higher than expected across both treatment arms, including loss of patients to ultrasound examinations, and a lower than expected overall event rate, both of which contributed to the study being underpowered.
The key safety outcome of major bleeding was low in both groups but occurred in more patients treated with apixaban for 30 days than with enoxaparin for a minimum of six days and a maximum of 14 days. At Day 30, major bleeding occurred in 0.47 percent of patients in the apixaban group and 0.19 percent of patients in the enoxaparin group (P=0.04). Major and clinically relevant non-major bleeding occurred in 2.67 percent of patients who received apixaban and in 2.08 percent of patients who received enoxaparin (P=0.12).
Other measures of overall safety were similar for apixaban and enoxaparin in ADO PT. Among the safety endpoints of adverse events, serious adverse events, deaths, discontinuation due to AE s, and liver function test (LFT) elevations; apixaban appeared to be similar to enoxaparin.
About Venous Thromboembolism
Venous thromboembolism encompasses two serious conditions: deep vein thrombosis, a blood clot in a vein, usually in the leg that partially or totally blocks the flow of blood; and pulmonary embolism, a blood clot blocking a vessel in the lungs. Deep vein thrombosis causes multiple symptoms including pain, swelling and redness and, more importantly, can progress to pulmonary embolism, which carries the risk of sudden death.
About ELIQUIS
ELIQUIS is the approved trade name for apixaban in Europe and the proposed trade name in the U.S. The companies recently announced the regulatory application for stroke prevention in atrial fibrillation was validated for review by the European Medicines Agency. The alliance expects to have an accepted filing in the U.S. for this indication by the end of 2011.
ELIQUIS is being investigated within the EXPAN SE Clinical Trials Program, which is projected to include nearly 60,000 patients worldwide across multiple indications and patient populations and includes a total of nine completed or ongoing, randomized, double-blind Phase 3 trials including ADO PT. ELIQUIS is currently being evaluated in ongoing trials for the treatment of recurrent VTE , in the Phase 3 AM PLIFY and AM PLIFY-EXT trials.
About the Bristol-Myers Squibb/Pfizer Collaboration
In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol- Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews . Pfizer Inc.: Working together for a healthier world(R)
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. W strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. -6-
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the companies will submit regulatory filings for apixaban for an indication in VTE prevention or that apixaban would receive regulatory approval for such indication. There is also no guarantee that, if approved in this indication, apixaban will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol- Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2010, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol- Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
PFIZER DISCLOSURE NOTICE:
The information contained in this release is as of November 13, 2011. Pfizer assumes no obligation to update forward looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about various potential indications for ELIQUIS (apixaban), including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical trial completion dates and regulatory submission dates; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for any such indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of any such indications; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended
Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk
ORLANDO , FL— Patients using Pradaxa (dabigatran), a new blood thinner aimed at preventing stroke and blood clots, failed to remain on the treatment 17 percent of the time after the first four months, according to a study presented at the American Heart Association’s Scientific Sessions.
The research conducted by Medco Research Institute(TM ), a subsidiary of Medco Health Solutions, Inc. MHS -0.41% , is the first real-world study to examine dabigatran’s use since its introduction last year. Dabigatran is an alternative to the popular blood-thinner warfarin, a drug dating to the 1950s and sold under the brand names Coumadin® and Jantoven®. Warfarin can be difficult to dose properly and patients need to be monitored closely to prevent bleeds or blood clots. The study showed that warfarin therapy was prescribed in 71 percent of patients during the prior 6 months to starting dabigatran treatment, suggesting that prescribers are adopting dabigatran as an alternative to warfarin.
“Dabigatran is indicated to prevent serious health conditions such as stroke and systemic embolism in patients with nonvalvular atrial fibrillation, so we wanted to examine how people are using the medication, and more importantly, if patients are staying on this vital therapy,” said Dr. Eric Stanek, vice president of research at Medco. “We are seeing a sizable proportion of patients drop off treatment in a fairly short time. This is a twice-daily drug and stroke prevention outcomes may be particularly sensitive to how consistently patients take it, pointing to a need and opportunity to provide dedicated and proactive patient support.”
“We have begun to engage patients with gaps in their dabigatran therapy, and our specialist pharmacists help them get back to taking it as prescribed or notify their doctors to consider an appropriate alternative,” said Dr. Donald Pittman, national practice leader of the Medco Cardiovascular Therapeutic Resource Center®. “Our data show the importance of actively monitoring the course of therapy in patients taking dabigatran. No matter how
effective it can be at preventing a stroke, it won’t work if patients don’t take it, which means doctors and pharmacists need to regularly monitor persistence and discuss adherence to therapy with dabigatran.”
Researchers also found higher associated short-term rates of hospitalization for stroke and systemic embolism and bleeding than was reported in a previous clinical trial with dabigatran in September 2009; the Randomized Evaluation of Long-Term Anticoagulation Therapy study (RE -LY) was a head-to-head study of the drug versus warfarin. The RE -LY study found patients who received dabigatran 150 mg twice a day had a similar bleeding risk, but a lower incidence of stroke and blood clots compared to warfarin. Dabigatran is usually prescribed at 150 mg twice a day; however, some patients with reduced kidney function should receive 75 mg twice a day.
“It’s not unusual to see a difference in event rates between clinical trials and the ‘real-world’ experience when it comes to newly-marketed prescription drugs,” Stanek said. “This further highlights the need for continuous surveillance of anticoagulant drug effectiveness and safety, as well as the opportunity to conduct longer-term comparative outcome studies on warfarin and alternative agents such as dabigatran and rivaroxaban.” Stanek added “It will be particularly interesting to further explore the role of warfarin pharmagenomics in such a comparison, and we have plans underway to do just that.”
Study Details
Medco examined de-identified prescription claims between Nov. 1, 2010 and Dec. 31, 2010 for 1,143 patients prescribed dabigatran for up to four months of follow-up. Medical diagnoses were determined by de-identified medical claims. Demographic and clinical characteristics of patients, prescriber specialty, 4-month persistence to dabigatran therapy, and hospitalization for stroke or systemic embolism and bleeding were assessed. Persistence to the medication at 120 days was calculated allowing a 45-day supply gap. The average patient was 73 years old, and was using nine chronic medications. Medical history over the 12 months prior to initiating dabigatran included: stroke (10 percent); venous thromboembolism (5 percent); pulmonary embolism (5 percent); valve replacement (2 percent). About 19 percent had a prior history of bleeding, and 13 percent did not have a medical claims history of atrial fibrillation. Patients received their dabigatran prescriptions mainly through retail pharmacies. Overall, cardiologists were the highest prescribers (62 percent), followed-by primary care physicians (23 percent).
The study was presented at the American Heart Association Scientific Sessions 2011 in Orlando, FL. Stanek, Barnabie C. Agatep, Vivian Herrera, Gosia Hawk, Bruce J. Schrader, Pittman, Felix W. Frueh, and Scott L. Charland (senior investigator) authored the study.
About Medco Research Institute
Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs.
More information about the Medco Research Institute’s peer-reviewed research can be found at www.medcoresearch.com .
About Medco
Medco Health Solutions, Inc. MHS -0.41% is pioneering the world’s most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter(TM ) for approximately 65 million members.
With more than 20,000 employees worldwide dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2010 revenues of nearly $66 billion, Medco ranks 34 th on the 2011 Fortune 500 list and is named among the world’s most innovative, most admired and most trustworthy companies.
For more information, go to http://www.medcohealth.com.
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company’s Annual Report on Form
10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
Gore Receives FDA Approval for Conformable
GORE® TAG® Thoracic Endoprosthesis
FLAG STA FF, AZ . & NEW YOR K -- W. L. Gore & Associates, Inc. (Gore) announced that it has received approval from the US Food and Drug Administration (FDA ) to market the Conformable GORE ® TAG ® Thoracic Endoprosthesis as a minimally invasive treatment for patients suffering from thoracic aortic aneurysms (TAA s). Today’s announcement came at the VEIT H Symposium 2011 Conference in New York. The device is the only FDA approved ePTFE thoracic endoprosthesis designed for endovascular repair of the descending thoracic aorta that offers conformability and ease of use, while accommodating tapered anatomy and resisting compression. The broad oversizing window for the device ranges from 6-33 %, allowing physicians to choose the appropriate oversizing for the patient anatomy.
William Jordan, MD , Chief of Vascular Surgery at the University of Alabama, Birmingham, served as national principal investigator for the Conformable GORE TAG Device in the Thoracic Aortic Aneurysm Trial (Gore
TAG 08-03) over the past two years. According to Dr.Jordan, “This new device represents a substantial product improvement brought to us by a company that was already leading the market in aneurysm devices. Gore evaluated the real world results of the first generation endograft and engineered improvements so that the device can be used across a wider range of aortic diameters with stronger radial force to resist compression. These modifications are intended to improve the lives of our patients and provide better outcomes for challenging clinical problems.”
The following physicians completed successful procedures using the Conformable GORE TAG Thoracic Endoprosthesis during the first week of release:
-- William McMillan, MD -- Vascular Surgeon at Minneapolis Vascular Physicians
-- Robert Mitchell, MD -- Thoracic Surgeon at Central Baptist Hospital, Lexington, Kentucky
-- Brian Peterson, MD -- Vascular Surgeon in the Department of Surgery at Saint Louis University
-- Robert Rhee, MD - Associate Professor of Surgery at the University of Pittsburgh Medical Center
-- Joshua Rovin, MD - Cardiovascular Surgeon at Bayfront Medical Center, St. Petersburg, Florida
-- Daniel Watson, MD -- Director of Endovascular Surgery at Riverside Methodist Hospital, Columbus, Ohio
The device is available in diameters of 21-45 mm, allowing for the treatment of patients with aortic diameters of 16-42 mm. Tapered device configurations are also available.
TAA s are a serious health risk because they can burst or rupture with little or no symptoms after developing over years. A ruptured aneurysm can cause severe internal bleeding, which can rapidly lead to shock or death. Thoracic aneurysms affect approximately 15,000 people in the US each year. Some patients may have more than one TAA or may also have an aneurysm of the abdominal aorta. Due to the high mortality risk associated with undetected and untreated TAA s, it is critical to get screened for aneurysm risk and seek early treatment if detected.
“The GORE TAG Device has been a leading endovascular treatment option for safely and effectively treating patients with aneurysms of the descending thoracic aorta. The device is backed by a proven safety record with more than 50,000 devices distributed worldwide and a decade of worldwide clinical data,” said David Abeyta, Gore Aortic Business Leader. “Now featuring design enhancements such as a modified stent frame, optimized graft film layers, enhanced conformability, and expanded oversizing ranges, the Conformable GORE TAG Device provides an optimal fit and maximum conformability for each patient’s anatomy without compromising conformability.”
ABOUT W. L. GORE & ASSOCIATE S
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 14th consecutive year.
For more information, visit www.goremedical.com . Products listed may not be available in all markets. GORE®, TAG®, and designs are trademarks of W. L. Gore & Associates. SOURCE: W. L. Gore & Associates, Inc.
